Botanical drug specialist Phytopharm suffered a setback yesterday
when Pfizer withdrew from a collaboration to develop P57, a drug
for obesity and metabolic syndrome.
A US appeals court has reversed an earlier decision to make
Switzerland's Roche pay almost $500 million in damages to Igen in a
dispute over a technology used in clinical diagnostics and
pharmaceutical research.
Dutch firm Crucell has expanded its licensing agreement with US
drug major Merck & Co relating to PER.C6, the former's
proprietary cell technology platform used for the production of
biopharmaceutical products.
Cambridge Antibody Technology of the UK has signed up for a
non-exclusive licence to a technology, developed by Canada's
Chromos Molecular Systems, for the commercial manufacture of
biologics.
